ENANTA PHARMACEUTICALS INC

ENTASEC EDGAR

Pharmaceutical PreparationsCIK: 1177648

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$79.2M	$86.2M	$97.1M	$122.5M	$205.2M
Research and Development Expense	$163.5M	$164.5M	$174.1M	$136.8M	$142.2M
Operating Income (Loss)	-$137.2M	-$123.8M	-$109.6M	-$41.6M	$36.7M
Interest Expense	—	—	$0.00	—	—
Nonoperating Income (Expense)	$6.2M	$1.7M	$2.0M	$6.6M	$8.8M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$131.0M	-$122.2M	-$107.6M	-$35.0M	$45.6M
Income Tax Expense (Benefit)	$2.8M	-$433.0K	-$28.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$376.7M	$462.3M	$375.4M	$438.8M	$486.1M
Assets, Current	$299.9M	$422.8M	$311.7M	$319.0M	$436.8M
Cash and Cash Equivalents, at Carrying Value	$37.2M	$85.4M	$44.0M	$57.2M	$87.1M
Accounts Receivable, after Allowance for Credit Loss, Current	$6.6M	$8.6M	$20.3M	$23.6M	$23.5M
Liabilities	$247.8M	$245.5M	$54.1M	$39.4M	$30.6M
Liabilities, Current	$57.5M	$62.8M	$29.8M	$36.2M	$24.2M
Accounts Payable, Current	$8.0M	$4.1M	$6.0M	$9.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$103.2M	-$84.8M	-$70.0M	$7.1M	$71.4M
Net Cash Provided by (Used in) Investing Activities	-$53.6M	$54.9M	$37.0M	$19.8M	-$86.7M
Net Cash Provided by (Used in) Financing Activities	$198.1M	$20.0M	$3.1M	$9.0M	$2.6M
Payments to Acquire Property, Plant, and Equipment	$9.1M	$2.1M	$750.0K	$1.4M	$5.4M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)